Home / Health / New Blood Test Spots Pancreatic Cancer Early
New Blood Test Spots Pancreatic Cancer Early
17 Sep
Summary
- Experimental blood test, PANXEON, detects early pancreatic cancer with 87% accuracy.
- Test identifies precancerous high-grade dysplasia, potentially preventing cancer.
- AI combines blood markers for a comprehensive pancreatic cancer risk score.
An experimental blood test named PANXEON has demonstrated significant success in identifying early-stage pancreatic cancer, offering new hope for a disease with a low survival rate. The test correctly detected early-stage pancreatic cancer in 87% of cases during a recent study.
Beyond detecting cancer, PANXEON also identified a precancerous condition known as high-grade dysplasia. This capability could allow for medical intervention before cancer fully develops, potentially saving lives. The test analyzes genetic material shed by cancer cells and a protein called CA19-9.
Artificial intelligence integrates these findings into a single score to assess a patient's pancreatic cancer risk. Researchers tested PANXEON across the U.S., Europe, and Asia, achieving a false-positive rate of 3% in low-risk groups and 16% in high-risk groups. The test detected high-grade dysplasia in over 64% of instances.
PANXEON is expected to benefit individuals with a genetic predisposition, family history, pancreatic cysts, or chronic pancreatitis. While larger studies are needed for widespread adoption, this development marks a crucial step toward earlier detection and improved treatment options for pancreatic cancer.
